Zonalta and Liver Injury
The evidence provided does not address Zonalta (cenobamate) and liver injury; instead, it discusses Zonalon® Cream (topical doxepin), which is an entirely different medication used for pruritic eczema, not epilepsy. Based on the available research evidence on cenobamate, there is no established association between cenobamate and direct hepatotoxicity, though enzyme induction effects have been documented.
Key Findings on Cenobamate (The Actual Drug)
Hepatic Enzyme Induction
- Cenobamate demonstrates hepatic enzyme-inducing properties, evidenced by statistically significant increases in serum gamma-glutamyl transferase (GGT) levels after 12 months of treatment 1
- This enzyme induction is similar to other anti-seizure medications but does not necessarily indicate liver injury or hepatotoxicity 1
Clinical Safety Profile
- Real-world observational studies of cenobamate in drug-resistant focal epilepsy show favorable retention rates, with 65.2% of patients having favorable responses over a median treatment duration of 655 days 2
- Among 145 patients treated with cenobamate, discontinuation occurred in 33.1%, with 35 patients stopping due to adverse effects and 6 due to lack of efficacy—notably, liver injury was not cited as a reason for discontinuation 2
- The most common adverse effects leading to discontinuation were not hepatic in nature 2
Metabolic Effects vs. Hepatotoxicity
- Cenobamate's primary documented effects involve metabolic changes (glycemic control, lipid profiles) and bone metabolism rather than direct liver injury 1, 3
- The elevation in GGT reflects enzyme induction rather than hepatocellular damage, which would be characterized by elevated transaminases (ALT/AST) 1
Clinical Implications
Cenobamate does not appear to cause clinically significant liver derangement or hepatotoxicity based on current evidence. The documented GGT elevation represents enzyme induction—a pharmacokinetic effect that differs fundamentally from drug-induced liver injury 1.
Monitoring Recommendations
- While routine hepatic monitoring is not specifically indicated for cenobamate based on liver injury risk, baseline and periodic GGT monitoring may be useful to document enzyme induction effects 1
- Patients on concomitant medications metabolized hepatically may require dose adjustments due to cenobamate's enzyme-inducing properties 1
Important Caveat
The provided FDA drug label evidence pertains to Zonalon® Cream (topical doxepin), not Zonalta/cenobamate 4. This represents a critical distinction, as these are completely different medications with different routes of administration, indications, and safety profiles. Topical doxepin undergoes hepatic metabolism and can cause systemic effects, but this information is irrelevant to cenobamate 4.